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ABSTRAK 
AKTIVITI PEMBEZAAN DAN PROLIFERASI TURUNAN SEL FETAL 
OSTEOBLAS MANUSIA (hFOB 1.19) YANG DIRAWAT DENGAN 
POLIFENOL, ASID TANIK SENDIRIAN ATAU GABUNGAN DENGAN 
PAMIDRONATE  
 
ABSTRAK 
Tulang sentiasa melalui proses pembentukan semula tulang dan ketidakseimbangan 
dalam proses tersebut mampu menyebabkan penyakit tulang, osteoporosis. Asid tanik 
(TA) adalah polifenol dengan kandungan antioksidan yang mungkin meningkatkan 
metabolisme tulang. Sinergisme adalah salah satu dari kesan farmakologi yang berlaku 
apabila gabungan banyak drug digunakan. Oleh itu, kajian ini dijalankan untuk memerhati 
kesan TA sendirian dan gabungan antara TA dan pamidronate terhadap pembezaan, 
proliferasi, pemineralan dan juga morfologi sel fetal osteoblast manusia (hFOB 1.19). Sel 
hFOB 1.19 dirawat dengan TA sendirian dan gabungan antara TA dan pamidronate yang 
pelbagai pada kepekatan yang berbeza (0.1 hingga 99.0 µg/ml). Kepekatan efektif median 
(EC50) untuk TA, pamidronate dan nisbah gabungan yang berbeza (25:75, 50:50, 75:25) 
diukur menggunakan ujian MTT. Analisis kesan sinergi turut dijalankan terhadap ratio 
kombinasi yang berbeza berdasarkan Indeks Gabungan (CI) di mana CI < 1: sinergisme, 
CI = 1: kesan tambah (additive) and CI > 1: antagonisme. Rawatan gabungan dengan nilai 
EC50 yang paling rendah dan CI<1 dipilih untuk kajian yang selanjutnya. Asai proliferasi 
sel dijalankan untuk membandingkan bilangan kebolehhidupan sel and morfologi sel 
hFOB 1.19 diperhatikan menggunakan mikroskop songsang dari hari pertama hingga hari 
ke-7. Berikutnya, penilaian pemineralan kalsium dan fosfat dilakukan menggunakan 
kaedah pewarnaan histokimia. Pengesanan gen spesifik tulang [bone sialoprotein (BSP) 
xv 
 
dan osterix (Osx)] dilakukan dengan menggunakan ujian tindak balas rantai polymerase 
(PCR). EC50 untuk sel hFOB 1.19 yang dirawat dengan TA sendirian (0.56 ± 0.22 µg/ml) 
dan gabungan nisbah 75:25 TA dan pamidronate (0.48 ± 0.03 µg/ml) didapati lebih 
berkesan berbanding pamidronate sendirian (15.27 ± 0.22 µg/ml) dan gabungan yang lain 
[(25:75; 3.80 ± 0.13 µg/ml); (50:50; 2.25 ± 0.11 µg/ml)]. Analisis sinergi menunjukkan 
hanya gabungan 75:25 mempamerkan kesan sinergi manakala gabungan lain 
menunjukkan kesan antagonis. Kesemua kumpulan menunjukkan perubahan ketara 
apabila dibandingkan antara hari pertama dan ke-7. Bagaimanapun, semua kumpulan 
kecuali kumpulan gabungan menunjukkan perubahan yang ketara apabila dibandingkan 
antara hari ke-3 dan ke-7. Apabila perbandingan dibuat pada hari yang sama, iaitu hari 
ke-7, kedua-dua kumpulan TA dan pamidronate sendirian menunjukkan peningkatan 
yang ketara untuk proliferasi sel berbanding kumpulan kawalan (tidak dirawat) dan 
gabungan. Sel hFOB 1.19 yang dirawat dengan kumpulan TA dan kombinasi mempunyai 
morfologi yang seragam dan bentuk memanjang hingga akhir kajian. Sel yang dirawat 
dengan TA sendirian mempunyai pembentukan deposit kalsium dan fosfat berbanding 
kumpulan kawalan, pamidronate dan gabungan. Kesemua kumpulan menunjukkan 
ekspresi gen BSP dan Osx sehingga hari ke-7. Kesimpulannya, TA sendirian mempunyai 
kebolehan meningkatkan proliferasi dan morfologi sel yang lebih baik di samping 
pemineralan osteoblast berbanding kumpulan gabungan TA dan pamidronate.  
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DIFFERENTIATION AND PROLIFERATION ACTIVITIES OF HUMAN 
FOETAL OSTEOBLAST CELL LINE (hFOB 1.19) TREATED WITH A 
POLYPHENOL, TANNIC ACID ALONE OR IN COMBINATION WITH 
PAMIDRONATE 
 
ABSTRACT 
Bone continuously undergoes bone remodelling and imbalance in bone remodelling leads 
to bone pathogenesis, such as osteoporosis. Tannic acid (TA) is a polyphenol with 
antioxidant properties which may elevate osteoblast metabolism. Synergism is one of 
pharmacological effect that occur when drug combination is used. Hence, the aim of this 
study was to evaluate the effect of TA alone and combination of TA and pamidronate on 
differentiation, proliferation, mineralisation as well as morphology of human foetal 
osteoblast cells (hFOB 1.19). The hFOB 1.19 cells were treated with TA alone and 
combination of TA and pamidronate of different combination ratios at different 
concentrations (0.1 to 99.0 µg/ml). Half maximal effective concentration (EC50) for TA 
alone, pamidronate alone and different combination ratios of TA and pamidronate (25:75, 
50:50, 75:25) were measured by using MTT assay. Analysis of synergistic effects was 
also performed on the different combination ratios based on Combination Index (CI) 
where CI < 1: synergism, CI = 1: additive effect and CI > 1: antagonism. The combination 
treatment with the lowest EC50 and CI<1 was then chosen for the next studies. Cell 
proliferation assay was conducted to compare the cell viability and morphology of hFOB 
1.19 cells was observed by using inverted microscope after treatment from day 1 to day 
7. In addition, detection of calcium and phosphate deposits were done by histochemical 
staining. Detection of bone specific genes [bone sialoprotein (BSP) and osterix (Osx)] 
was conducted by polymerase chain reaction (PCR) test. The EC50 of hFOB 1.19 cells 
xvii 
 
treated with TA alone (0.56 ± 0.22 µg/ml) and 75:25 ratio of TA and pamidronate (0.48 
± 0.03 µg/ml) were more effective compared to pamidronate alone (15.27 ± 0.22 µg/ml) 
and other combination ratios treatments [(25:75; 3.80 ± 0.13 µg/ml); (50:50; 2.25 ± 0.11 
µg/ml)]. Analysis of synergistic result showed that only 75:25 combination ratio exhibited 
synergistic effect while the other two combination ratios manifested antagonistic effects. 
All groups showed significant different when compared between day 1 and day 7. 
However, all groups except combination group manifested significant different when 
comparing between day 3 and 7. When comparing on similar day which was day 7, both 
TA alone and pamidronate alone treated groups showed significantly increased in cell 
proliferation compared to control (untreated) and combination groups. The morphology 
of hFOB 1.19 cells treated with both TA and combination groups had uniform and 
elongated shape until the end of study. Treatment with TA alone demonstrated higher 
production of calcium and phosphate deposits compared to untreated control, 
pamidronate alone and combination groups. All groups manifested the expression of BSP 
and Osx until day 7 of treatment periods. In conclusion, TA alone rather than combination 
treatment of TA and pamidronate has greater ability in enhancing cell proliferation and 
morphology besides improved osteoblast mineralisation.  
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CHAPTER 1 
INTRODUCTION 
1.1 Background of study  
Bone involves in structural support of the body, locomotion, mineral storage and storage 
of bone marrow (Nam & Kampa, 2013; Florencio-Silva et al., 2015). Bone also constantly 
undergoes two processes throughout life which are modelling and remodelling. Modelling 
helps bone adapt to changing biomechanical forces while remodelling helps to remove 
old and micro-damaged bones to new and mechanically stronger bone which brings to 
reservation of bone strength. Bone modelling usually occurs during growth where bone 
becomes widen however it may increase in pathophysiology such as hypoparathyroidism, 
renal osteodystrophy or patient of anabolic agents. Bone remodelling on the other hand, 
keeps repeating removed the old and damaged bone from birth until death (Clarke, 2008).  
Bone remodelling is important in order to replace the infantile bone to secondary 
bone which is more stable and competent, remove ischemic or micro-fractured bone and 
amend calcium homeostasis (Rucci, 2008). There are three main phases in bone 
remodelling; 1) bone resorption by osteoclasts, 2) the transition from resorption to new 
bone formation or reversal and 3) the bone formation by osteoblasts. The process is 
regulated by basic multicellular unit (BMU), a temporary anatomical structure formed of 
osteoclasts, osteoblasts, osteocytes and bone lining cells. During bone formation, 
osteoblasts secretes collagenous and non-collagenous proteins such as osteocalcin, 
osteopontin, osteonectin, bone sialoprotein (BSP) and bone morphogenetic proteins 
(BMPs) (Florencio-silva et al., 2015). In vitro data suggest that BSP may initiate 
hydroxyapatite crystal formation in the bone matrix (Hunter & Goldberg, 1994). Besides, 
an active osteoblast also highly secretes osterix (Osx) which is one of the earliest bone 
formation marker which decreases as osteoblasts becomes osteocytes (Zhang et al., 2011).  
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The disturbance in bone remodelling process can lead to metabolic bone disease 
and skeletal system disorder such as osteoporosis. The disturbance is caused by oxidative 
stress which is a condition of overproduction of reactive oxygen species (ROS). ROS 
causes apoptosis of osteoblasts and osteocytes which leads to imbalance in bone 
remodelling process by decrease bone formation and favour bone loss by osteoclasts 
(Domazetovic et al., 2017).  
The World Health Organization (WHO) defines osteoporosis as a metabolic and 
progressive bone disease manifested by reduced bone mass and altered microarchitecture 
of the bone which increased risk of fracture (Lau & Guo, 2011; Rao & Rao, 2013; Ferdous 
et al., 2015). Between the periods of 2010 to 2050, osteoporosis is predicted to become 
major public health threat which will result in 8.1 million fractures in 78% women and 
22% men (Lao & Guo, 2011). This metabolic disease usually occurs in elder people as a 
“silent thief” as there are no noticeable symptoms until it demonstrates as fragility fracture 
(Jahanian et al., 2016). 
Pamidronate (a type of bisphosphonate) is mainly used in the treatment of 
osteoporosis by inhibiting bone resorption by osteoclasts during bone remodelling 
(Daroszewska, 2015). Besides their inhibitory effect towards osteoclasts, pamidronate 
also enhances production of collagen type I which eventually increased bone density and 
osteoblast differentiation (Koch et al., 2010). However, bisphosphonate is inadequately 
absorbed, needs to be taken separately from food and has many side effects such as 
gastrointestinal problems, pain in muscles or joints and headache. Moreover, other 
treatment such as oestrogen or hormone therapy may cause vaginal bleeding, gallbladder 
disease and clots in the veins (Ferdous et al., 2015). 
In that regard, community nowadays have shift their interests to natural products 
such as herbal medicines which are now considered important as they are believed to be 
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free from harmful chemicals and side effects (Sooi & Keng, 2013). This can be seen in 
Chinese community as Chinese herbal medicine is used as preventive agents or treatment 
on early stage of osteoporosis (Che et al., 2016). 
Plants have phytochemicals which protect them from microbial infections or 
damage from pests. The phytochemicals also have medicinal values in maintaining 
human health and disease treatments (Shakya, 2016). Polyphenols are example of 
phytochemical that widely found in plants which have many medicinal values such as 
prevention against cardiovascular diseases, cancer, diabetes and osteoporosis (Rajesh et 
al., 2016). Polyphenols have antioxidant properties which can prevent osteoporosis by 
scavenging ROS and down-regulating inflammatory mediators and help in bone 
formation by up-regulating bone formation markers such as runt related transcription 
factor-2 (Runx2), osteocalcin, Wnt signalling pathway, β-catenin and insulin-like growth 
factor (IGF)-1 (Hubert et al., 2014; Torre, 2017).  
Tannic acid (TA) is a polyphenol classified from tannins group which has 
antioxidant properties (Horcajada & Offord, 2012; Chung et al., 1998). European Union 
Regulation (EUR) stated that TA is a food flavouring and has been extensively used as 
preservatives (Arapitsas, 2012; Hu et al., 2015). Antioxidants activate the differentiation 
of osteoblasts and prevent the action of ROS directly (Domazetovic et al., 2017). There 
is currently no specific research has been conducted regarding TA and bone formation or 
osteoporosis treatment. However, there are many researches had been conducted by using 
plants which have tannins. Thakur et al. (2016) in their study had used Saraca indica 
which has tannins as antiosteoporotic on Wistar rats which had been induced by 
dexamethasone to develop osteoporosis. They found out that the plant increased bone 
density and biomechanical strength of the rats. By using in-vitro technique, Thu et al. 
(2017) had studied the effects of Eurycoma longifolia on proliferation and differentiation 
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of osteoblast. E. longifolia had positive effects on osteoblast proliferation and 
differentiation with the deposition of calcium and phosphate was significantly expressed 
at the concentration of 25 µg/ml.  
Drug combination studies are usually targeting on achieving synergistic treatment 
effect, dose and toxicity mitigation as well as to minimise or delay the induction of drug 
resistance (Chou, 2012). The net effects of drug combination include synergism or 
additive effect, antagonism or substractive effect and alteration of effect of one or more 
drugs (Nidhi, 2012). Combination treatment in osteoporosis such as combination of 
oestrogen and bisphosphonate is often given to the patient of osteoporosis rather than 
non-combination or single agent as it is more effective in increasing bone mineral density 
(BMD) (Tella & Gallagher, 2014). Oestrogen helps in treating osteoporosis patient by 
inducing apoptosis of osteoclasts which decreases resorption of bone and increase 
osteoblast lifespan which enhances bone formation (Imai et al., 2009; Khosla et al., 2012).  
The research which involved combination of herbal medicines and 
antiosteoporosis drug had been conducted by Ko et al. (2012), which studied the 
pharmacological effects of a Chinese Herbal Formula Epimedii Herba, Ligustri Lucidi 
and Psoralea Fructus (ELP) and anti-resorptive drugs (alendronate and raloxifene) to 
prevent osteoporosis in rats. The herbal formula had been shown to increase the 
promotion of osteogenic differentiation in rat mesenchymal stem cells by elevating 
alkaline phosphatase (ALP) activity and matrix calcium deposition. The herbal formula 
was found to have different effects on the antiresorptive drugs. It increased the bone 
protective effect of raloxifene while did not produced synergistic effect when used 
together with alendronate. Another combination study was also done by Raudhah et al. 
(2018) by using combination of pamidronate and semi-purified fractions of Quercus 
infectoria (QI) which had positive effects on proliferation and differentiation of 
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osteoblasts. The level of bone formation markers (Runx2 and Osx) were higher in 
combination treatment compared to single treatment of pamidronate and Q. infectoria 
(QI). In this current study, a single compound of TA was used rather than the crude or 
semi-purified fractions of plant extract which consists of numerous compounds. For 
example, liquid chromatography mass spectrometry (LC-MS) analysis of each QI semi-
purified fraction reveals the presence of polyphenolic compounds (gallic acid, digallate, 
ellagic adid, phaseolic acid, syringic acid and theogallin) (Abdullah et al. 2018). 
Moreover, the extraction, purification and isolation procedures are complex and time 
consuming. A part from that, TA compound can be bought anytime while certain herbs 
that contains TA may only presence or can be collected during certain times.  
Thereby, the TA alone and in combination with pamidronate was used to study 
the proliferation and differentiation, morphology, mineralisation as well as BSP and Osx 
genes and proteins expression of osteoblast via various techniques such as microscopy 
observation, histochemical staining, polymerase chain reaction (PCR) and western blot. 
 
1.2 Problem statement 
As life expectancy of Malaysian becomes longer, osteoporosis also becomes a major 
concern in Malaysia. Osteoporosis may occur in both men and women at any age, 
however it commonly occurs in older women due to decreased level of oestrogen. Besides, 
the cost to treat and maintenance of osteoporosis-related morbidity is expensive as 
osteoporosis is usually detected when the disease had become worsen. Many synthetic 
drugs are available to treat osteoporosis, however they possess shortcomings in their 
efficacy. As a result, they need to be taken for long-term treatment. Nonetheless, these 
osteoporosis medications induce side effects which will get worsen with the long-time 
usage. This situation causes an urge in research and development to find potential and 
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safe alternative therapy such as using natural products especially phytochemical to 
decrease the side effects.  
Nowadays, drug discovery of herbal and drug combination therapies is getting 
spotlight to improve therapeutic efficacy and minimise the adverse effects of the 
osteoporosis drug through modern molecular biological methods. Although there were 
several studies conducted by using combination of herbal plant and anti-osteoporotic drug, 
however, there has been no scientific evidence and research on the effects of a specific 
polyphenol; tannic acid (TA) alone or in combination with control drug on bone being 
reported. Therefore, in this current study, it is proposed that TA with the presence or 
absence of control drug (pamidronate) can assist in bone remodelling process especially 
in relation to osteoblast metabolism. The osteoblast was employed in this study rather 
than using osteoclast or osteocyte as osteoblast is the main cell involved in bone formation. 
The bone formation process such as proliferation and differentiation of osteoblast as well 
as mineralisation were studied in this study by observing the morphological changes, 
expression of selected bone formation markers (BSP and Osx), along with the assessment 
of calcium and phosphate levels. 
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1.3 Objectives  
1.3.1 General objective 
To evaluate the effect of TA alone and in combination of TA and pamidronate on 
differentiation and proliferation activities and formation of mineralised deposits 
(calcium and phosphorus) of human foetal osteoblast (hFOB 1.19)  
 
1.3.2 Specific objectives 
1. To determine half maximal effective concentration (EC50) and proliferative 
activity of hFOB 1.19 cells after treated with TA alone and in combination of 
TA and pamidronate 
2. To determine combination index (CI) of the combination treatment between 
TA and pamidronate by synergistic analysis 
3.  To examine the morphological changes of hFOB 1.19 cells after treated with 
TA alone and in combination of TA and pamidronate using inverted 
microscope 
4. To evaluate the formation of mineralised deposits (calcium and phosphate) of 
the hFOB 1.19 cells after treated with TA alone and in combination of TA and 
pamidronate by using histochemical staining (von Kossa and Alizarin Red S) 
5. To investigate the expression of osteoblast proliferation markers BSP and Osx 
of the hFOB 1.19 cells after treated with TA alone and in combination of TA 
and pamidronate by using polymerase chain reaction (PCR)  
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Bone 
2.1.1 Structure and function of bone 
There are five general types of bones based on their shapes; long bones, short bones, flat 
bones, irregular bones and sesamoid bones (Figure 2.1). Long bones include the clavicles, 
humeral, radii, ulnae, metacarpals, femurs, tibiae, fibulae, metatarsals and phalanges. 
Meanwhile, short bones include the carpal, tarsal bone, patellae and sesamoid bones. Flat 
bones comprise of the skull, mandible, scapulae, sternum and ribs. Irregular bones include 
the vertebrae, sacrum, coccyx and hyoid bones. Lastly, sesamoid bones are bones which 
placed within a tendon and they can be found in the hand, knee and foot. Their functions 
are to preserve the tendons and increase the mechanical effect of the tendons (Clarke, 
2008; National Register of Personal Trainers, 2018).  
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Figure 2.1: Types of bones; long bones, short bones, flat bones, irregular bones and sesamoid 
bones. (Adapted from Lumen Learning, n.d.) 
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Bones also divide into immature and mature bone where immature bone tissue is 
known as primary woven bone tissue while mature bone tissue is known as secondary 
lamellar bone tissue. Woven bones present in foetal bones at the first-time bones are 
produced and after fractures in the adult. The bones are later replaced by lamellar bone as 
woven bone is immature bone or pathologic bone. Woven bones get their name via their 
woven appearance of fibrous matrix (Figure 2.2) (Singh, n.d.).  
 
 
 
 
 
 
 
Figure 2.2: Woven bone with presence of abundant fibrous matrix (Adapted from Singh, n.d.)  
 
Remodelling of woven bones produce lamellar bones. Lamellar bones got their 
name due to arrangement of collagen in parallel form or lamellae form. Different with 
woven bones which has more osteocytes per unit volume, lamellar bones have lower 
amounts of osteocytes to surrounding tissue and are filled with many collagen fibres 
parallel to each other in same layer known as osteons or Harversian system. Among the 
different layer, the fibres run in opposite directions which creates structural arrangement 
helps in bone ability to withstand torsion forces (Singh, n.d.).  
Collagen 
fibres 
Woven 
bone 
11 
 
There are two types of lamellar bone tissue which are the cortical bone (compact 
bone) and trabecular bone (cancellous bone) (Figure 2.3). Both types of tissue share same 
matrix composition while having different structure and function. Cortical bone is dense, 
solid and encloses the marrow space while the trabecular bone is cancellous or spongy 
bone tissue which is composed of a honeycomb-like network of trabecular plates and rods 
scattered in the bone marrow compartment (Clarke, 2008; Kini & Nandeesh, 2012; 
Weatherholt et al., 2012). Cortical bone is made up of osteons which are dense and 
parallel concentric lamellar units. Each osteon is connected to each other via Haversian 
system, Volkmann’s canals and canaliculi. Cortical bones are covered with connective 
tissue; periosteum on the outside and by endosteum in the inner surface. Trabecular bones 
are different compared to cortical bones as they are no vessels like canaliculi within 
trabeculae. Instead, they are nourished by diffusion from the surrounding bone marrow 
(Osterhoff et al., 2016). 80% of skeletal is made up of cortical bones. Cortical bones have 
a slow replace rate and a high resistance to bending and torsion. Thus, they made up the 
outer part of all skeletal structures as can be seen prominently within the cylindrical shaft 
of upper extremity long bones as cortical bones form a thick shell or cortex surrounding 
the medullary canal. As most part of cortical bone is calcified, its function is to give 
mechanical strength and protection. Besides, cortical bone also takes part in metabolic 
responses, especially when there is severe and continuous mineral deficit (Hadjidakis & 
Androulakis, 2006; Weatherholt et al., 2012).  
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Figure 2.3: Cortical and trabecular bones of lamellar bone (Adapted from Sami, 2015)
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Meanwhile, trabecular bone comprises 20% of skeletal structure and it has an 
outer periosteal surface and inner endosteal surface (Hadjidakis & Androulakis, 2006; 
Clarke, 2008). The periosteal surface is a fibrous connective tissue sheath that encloses 
the outer surface of bone except at joints as the bones there are lined by articular cartilage. 
It has blood vessels, nerve fibres, osteoblasts and osteoclasts. The functions of this outer 
surface are to protect, nourish and help in bone formation. Besides, it also plays important 
role in appositional growth and fracture repair. The inner endosteal surface on other hand 
is a membranous surface surrounding the inner surface of cortical and cancellous bone 
and the blood vessel canals (Volkmann’s canals) in the bone. Trabecular bone also offers 
mechanical support by having ability to spread load evenly and absorb energy around the 
joints area (Kini & Nandesh, 2012; Weatherholt et al., 2012).  
 
2.1.2 Histology of bone  
Histological composition of the bone tissue includes extracellular matrix, collagen and 
cells which involve in structural function (Hadjidakis & Androulakis, 2006). There are 
four different types of cell that make up the bone; osteoblasts, osteocytes, osteoclasts and 
bone lining cells (Figure 2.4 & 2.5) (Mohamed, 2008). Osteoblasts are mononucleated, 
cuboidal cells located along the bone surface and make up 4 to 6% of total bone cells (Lau 
& Guo, 2011; Florencio-Silva et al., 2015). They were named “osteoblast” as they 
literally produce bone. They are formed from multi-potential mesenchymal progenitors 
and they present for the whole life with their highest activity are during embryonic 
skeletal formation and growth (Nam & Kampa, 2013; Rutkovskiy, Stensløkken & Vaage, 
2016). The main function of osteoblasts is to produce the components that make up the 
extracellular matrix such as type I collagen, proteoglycans, and non-collagenous and cell 
attachment proteins (Mohamed, 2008). As they involve in bone formation process, they 
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show morphological characteristics of protein synthesizing protein, such as abundant 
rough endoplasmic reticulum, distinguished Golgi apparatus and variety of secretory 
vesicles (Florencio-Silva et al., 2015).  
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Figure 2.4: Histology of bone shown bone cells (Adapted from Pernick, 2016)  
 
 
 
Figure 2.5: Position of different bone cells in bone (Adapted from International Osteoporosis 
Foundation, 2017) 
 
 
 
Canaliculi 
16 
 
Osteocytes are produced when osteoblasts are trapped in the bone matrix and 
made up of about 95% of cells in the mature bone tissue with function of important 
controller of mechanical and hormonal signals (Mohamed, 2008; Long, 2012). Osteocytes 
are postproliferative and locate in the lacunae and are regularly distributed as many fine 
canals called canaliculi emit from them in all directions. The role of the canaliculi is to 
allow the diffusion of substance via the bone (Figure 2.3). Thus, many processes from the 
osteocytes go through the canaliculi in all direction, making osteocytes as main cells to 
detect stresses induced in bone and main mechanoreceptors of bone due to their 
widespread distribution and interconnections (Mohamed, 2008).  
Bone lining cells are inactive osteoblasts that line on the bone surface as a layer 
of flattened and elongated cells (Mohamed, 2008; Long, 2012). They are also known as 
periosteal surface which layered along outer cortical bone (Clarke, 2008). Along with 
osteocytes, they are also postproliferative and protect bone surface from any osteoclast 
resorptive activity. However, they may be reactivated to form osteoblasts (Mohamed, 
2008). They have a thin and flat nucleus, cytoplasm which broading along the surface and 
a few cytoplasmic organelles such as rough endoplasmic reticulum and Golgi apparatus 
(Florencio-Silva et al., 2015).  
Among all cells that form the bone, osteoclasts are the only cells which able to 
resorb bone. They are multinucleated cells which derived from monocyte or macrophage 
lineage (Lau & Guo, 2011). Presence of numerous organelles especially mitochondria 
show that osteoclasts are actively associated in energy production and protein synthesis, 
mainly production of lysosomal enzymes. Well defined cell polarity is shown by active 
bone-resorbing osteoclasts as their plasma membrane can be differentiated into three 
sections; clear zone, ruffled border and basolateral plasma membrane (Nakamura, 2007). 
The osteoclasts from long bone marrow are produced faster than in the jaw as the 
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osteoclastogenic potential of osteoclasts are different depends on the bone site they 
occupy which is due to cellular composition of the bone-site specific marrow (Florencio-
Silva et al., 2015). Life expectancy of the osteoclasts can be from 6 to 10 days depends 
on location and need (Nam & Kampa, 2013). Oestrogen able to reduce the life expectancy 
of the osteoclasts by promoting apoptosis (Lau & Guo, 2011).  
Inorganic salts and organic matrix make up bones. The extracellular matrix (ECM) 
is also known as osteoid when it first deposited but not yet mineralised. The ECM starts 
to mineralise via accumulation of crystalline hydroxyapatite [Ca3(PO4)2]3Ca(OH)2]. The 
inorganic salts of the bone are mainly phosphate and calcium ions which form the 
crystalline hydroxyapatite besides other ions such as bicarbonate, sodium, potassium, 
citrate, magnesium, carbonate, fluorite, zinc, barium and strontium (Feng, 2009; Long, 
2012; Fluorencio-Silva et al., 2015). The bone extracellular matrix is secreted by 
osteoblasts and at some points mineralized to build strength and hardness (Nam & Kampa, 
2013). Collagen I is the main collagen present in the matrix which constitute of 
approximately 90% of bone organic composition followed by types III and IV and FACIT 
collagens (Collagen IX, XII, XIV, XIX, XX, and XXI). FACIT collagens are important 
in organizing and stabilizing the matrix. Non-collagenous proteins such as proteoglycans, 
glycosylated proteins, glycosylated proteins with potential cell-attachment activities, and 
γ-carboxylated (gla) proteins also present to help to regulate matrix mineralization 
(Clarke, 2008; Kini & Nandeesh, 2012).  
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2.1.3 Physiology of bone formation 
Ossification or osteogenesis is the process of new bone formation by osteoblasts. The 
main components of this process are osteoblasts and bone matrix. This process can be 
divided into two more specific processes; intramembranous ossification and 
endochondral ossification (Figure 2.6) (Kini & Nandeesh, 2012). Intramembranous 
ossification occurs in the flat bones of the skull, facial bones, mandible and clavicle, it 
involves direct differentiation of embryonic mesenchymal cells the bone-forming 
osteoblasts while endochondral ossification occurs in other places of the skeleton and 
involves the replacement of a cartilage model by bone tissue (Mackie et al., 2011; Tortura 
& Derrickson, 2011). Intramembranous ossification is also present in the healing process 
of fractures treated by open reduction and stabilization by metal plate and screws. 
Meanwhile, endochondral ossification presents during fracture healing when treated by 
cast immobilisation (Kini & Nandeesh, 2012). 
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Figure 2.6: Intramembranous and endochondral ossification. A & B) development of cartilage 
model where mesenchymal cells differentiate into chondrocytes, C) chondrocytes undergo cell 
division caused growth of cartilage model which covered by perichondrium, D) development of 
primary ossification centre E) development of secondary ossification centres occurs in the 
epiphyses of the bone (Adapted from Egawa et al., 2014).  
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The intramembranous ossification involves four stages; 1) development of the 
ossification centre, 2) calcification, 3) formation of trabeculae and 4) development of 
periosteum. During the initial formation of bone, specific chemical messages will be 
secreted and cause the mesenchymal stem cells (MSCs) to cluster among themselves and 
differentiate into osteogenic cells and later into osteoblasts. The site where the MSCs 
cluster is called ossification centre and osteoblasts later continue to secrete the organic 
ECM until the bone is surrounded by ECM. Osteoid or unmineralised bone matrix is 
produced by osteoblasts in vesicle forms (Figure 2.3). It serves as a template for the later 
mineralised bone matrix when hydroxyapatite started to presence in these osteoid vesicles 
and become hydroxyapatite crystals which grow inside the vesicles and penetrate via the 
membrane to form mineralised nodules or calcified nodules. The mineralisation of bone 
matrix also eventually leads to collagen mineralisation when the hydroxyapatite crystals 
are continued being passage into the nodules and extends along the collagen fibrils. When 
the secretion of ECM stops, osteocytes start to migrate to canaliculi and scatter to all 
directions. Then, the calcium and other minerals begin deposited and the ECM calcifies. 
The ECM later develops to trabeculae and fuse with each other to form spongy bone 
around the blood vessels and connective tissues that trap in the trabeculae link with blood 
vessels and differentiate into red bone marrow. At the same time as production of 
trabeculae, the MSCs condense at the borderline of the bone and form periosteum or bone 
lining cells. After some time, compact bone replaces spongy bone with spongy bone 
remains in center (Ozawa et al., 2008; Tortora & Derrickson, 2011).  
Another type of ossification is endochondral ossification where the cartilage is 
replaced by bone. The steps of this ossification are 1) development of the cartilage model, 
2) growth of cartilage model, 3) development of primary ossification centre, 4) 
development of medullary (marrow cavity), 5) development of the secondary ossification 
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centre and 6) formation of articular cartilage and epiphyseal (growth) plate. In the 
beginning, the MSCs differentiate into chondroblasts which secrete ECM to produce a 
cartilage model made up of hyaline cartilage and is covered by perichondrium. The 
chondroblasts are later embedded in the ECM and is referred as chondrocytes which later 
undergo cell division along with secretion of cartilage ECM cause the cartilage model to 
increase in length. This process is known as interstitial or endogenous growth or growth 
from within. On the other hand, the cartilage model becomes thicker when ECM secreted 
by chondroblasts deposited on the cartilage surface in the appositional or exogenous 
growth process which is regulated by insulin-like growth factor (IGF) signalling. As the 
cartilage model keep on growing, chondrocytes stop dividing but start enlarging to 
proliferate into hypertrophic chondrocytes. While ECM also continues to calcify due to 
collagen type X secreted by hypertrophic chondrocytes, it becomes lack of nutrients and 
causes chondrocytes undergo apoptosis and the spaces left by died chondrocytes become 
small cavities; lacunae which eventually become vascularised (Tortura & Derrickson, 
2011; Egawa et al., 2014). 
The primary ossification centre later starts to develop from inward direction with 
a nutrient artery invades into the perichondrium and calcifies the cartilage model which 
later trigger MSCs in the perichondrium to differentiate into osteoblasts. The 
perichondrium starts to form bone and changes into periosteum. The primary ossification 
begins to form and spread from the centre when periosteal capillaries emerge into the 
disintegrating calcified cartilage. Osteoblasts also secrete ECM which later forming 
spongy bone over the calcified cartilage causes the calcified cartilage to be replaced with 
bone tissue. As the primary ossification forms from the centre to the ends of the bone, 
osteoclasts dissolve some of the newly produced spongy bone and causes a cavity called 
medullary or marrow cavity in the diaphysis or shaft of bone. The wall of the diaphysis 
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is then replaced by compact or cortical bone. The secondary ossification centre is later 
progress as epiphyseal artery enter the epiphyses region of bone. The bone formation 
during this process is similar in primary ossification centre except that no medullary 
cavity is formed as spongy bone remains in the inner side of epiphyses. In addition, the 
secondary ossification centre grows outward from the centre of epiphyses unlike the 
primary ossification centre. Lastly, the hyaline cartilage serves as epiphyseal or growth 
plate which later during adulthood becomes articular cartilage (Tortura & Derrickson, 
2011; Egawa et al., 2014).  
 
2.1.4 Osteoblast differentiation and proliferation 
Osteoblasts are derived from two different process; intramembranous and endochondral 
ossification. The multipotent MSCs are capable to differentiate into either of these cells; 
osteoblasts, adipocytes, chondrocytes, myoblasts and fibroblasts (Figure 2.7). Through 
the intramembranous ossification, the osteoblasts originate from neural ectoderm MSCs 
are form directly without any transitional stages that form squamous bones of the skull 
and face (calvaria) and part of the clavicle. Osteoblasts of the axial skeleton are derived 
from paraxial mesoderm while from lateral plate mesoderm for the appendicular skeleton. 
On the other hand, via endochondral ossification, the osteoblasts differentiate from an 
intermediate class of perichondral cells or directly from hypertrophic chondrocytes 
(James, 2013; Rutkovskiy, et al., 2016). 
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Figure 2.7: Multilineage differentiation of mesenchymal stem or stromal cells (MSC) (Adapted 
from James, 2013) 
 
  In the early stage, Wnt10b from wingless-int (Wnt) pathway involves in 
differentiation of MSCs into osteoblast or chondroblast progenitor while prevent 
differentiation of MSCs into preadipocyte via suppression of the adipogenic transcription 
factors CCAAT enhancer protein α (C/EBPα) and peroxisome proliferator-activated 
receptor γ (PPAR-γ) (Figure 2.8). Wnt10b also activates transcription factor Runx2, Msx2, 
distal-less homeobox 5 (Dlx-5) and β-catenin to promote osteoblastogenesis instead of 
chondrocyte differentiation. Osterix (Osx) also involves in osteoblastogenesis by 
promoting osteoblast progenitor into Pre-Osteoblast (Pre-OBL). Pre-OBL is identified as 
it secretes alkaline phosphatase (ALP), the type 1 parathyroid receptor (PTH1R) and 
alpha-1 type I collagen (Col1A1) as earliest markers. When the pre-OBL becomes active 
osteoblast (active OBL), it continues secretes ALP and Col1A1 along with osteopontin, 
osteocalcin, osteonectin and bone sialoprotein (BSP) (Rucci, 2008).  
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Figure 2.8: Differentiation and proliferation of osteoblast via intramembranous and endochondral 
ossification and the marker involved (Adapted from Rucci, 2008) 
 
Wnt signalling pathway involves in many important biological processes 
including tissue homeostasis, stem cell conservation, proliferation of cells, transformation 
of cancer cells and tumour suppression (Wend et al., 2012). The functions of Wnt family 
especially Wnt10b had been investigated via in vivo and in vitro. Longo et al. (2004) in 
their study had proved that under control of FABP4-promoter, transgenic mice which 
expressed Wnt10b had increased bone mass and strength besides Bennetts et al. (2005) 
found that those mice were resistant to aging or hormonal-related bone loss. Bennett et 
al. (2005) also found that by using in vitro technique on bone-marrow-derived St2 cells, 
Wnt/β-catenin signalling promotes osteoblastogenesis and increases mineralisation. 
However, the main function of Wnt10b is to trigger the expression of osteoblast 
transcription factors while suppresses the key adipogenic transcription factors so that the 
MSCs differentiate into osteoblasts instead of adipocytes (Wend et al., 2012).  
Runx2 is in Runx family and essential for both endochondral and 
intramembranous ossifications which produce osteoblasts. It also important for 
osteoblasts as matured osteoblasts need Runx2 for production of bone matrix. Runx2 is 
expressed in the chondrogenic mesenchymal with the help of Sox9 expression. When the 
